HealthVerity Releases its Provider Diversity Index 2023
Enhancements to the new edition support pharma and CROs to increase diversity in clinical trials, as well as align recruitment with disease incidence
HealthVerity has released its Provider Diversity Index (PDI) 2023 edition, which includes new enhancements such as age range, gender, income range, payer type (commercial, Medicare or Medicaid) and diagnosis.
First introduced in 2020, this nationally-syndicated report synchronizes medical, pharmacy and social determinants of health data from a large data ecosystem to calculate the racial diversity of patients for over 1 million physician practices, all in a HIPAA-compliant manner. The HealthVerity PDI is being used by pharma sponsors to identify clinical trial site investigators and to more effectively characterize and recruit patient populations that better reflect the diversity mix of diagnosed patients.
Alzheimer's is an example of a condition that disproportionately affects minorities. According to the Alzheimer's Association, 19% of Black/African American and 14% of Hispanic/Latino adults age 65 and older have Alzheimer's, compared to 10% of White/Caucasian seniors In contrast, participants in a 2020 clinical trial for an Alzheimer's medication were 86% White/Caucasian. Its PDI, says the company, could leverage diagnosis in a HIPAA-compliant manner to highlight physicians treating broader cohorts of minority patients whose recruitment could yield more effective clinical trial results.
"These statistics demonstrate how critical it is that researchers be able to work on clinical trials with physicians who have better access to patient populations representative of their particular study," said Andrew Kress, CEO of HealthVerity, in a press release.
Reference: HealthVerity releases the Provider Diversity Index 2023 edition to increase diversity in clinical trials. PHILADELPHIA, July 18, 2023. PRNewswire.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
